{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:35:04Z","timestamp":1791470104151,"version":"4.3.4"},"reference-count":122,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.eururo.2020.01.033","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:50:24Z","timestamp":1583715024000},"page":"614-627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"title":["Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review"],"prefix":"10.1016","volume":"77","author":[{"given":"Lisa","family":"Moris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus G.","family":"Cumberbatch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Van den Broeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6816-3725","authenticated-orcid":false,"given":"Nicola","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Briers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cornford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Grummet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.L.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lardas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Imran","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9804-0603","authenticated-orcid":false,"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodorus H.","family":"van Der Kwast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk G.","family":"van Der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter-Paul M.","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4374-3042","authenticated-orcid":false,"given":"Cathy Y.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrinath","family":"Konety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7429-4791","authenticated-orcid":false,"given":"Suneil","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2020.01.033_bib0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00345-008-0250-7","article-title":"High-risk prostate cancer in the United States, 1990\u20132007","volume":"26","author":"Cooperberg","year":"2008","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2012.08.001","article-title":"Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study","volume":"63","author":"Rider","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0015","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0020","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.eururo.2016.03.021","volume":"70","author":"Foss\u00e5","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0025","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1200\/JCO.2014.57.7510","article-title":"Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer","volume":"33","author":"Mason","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eururo.2012.03.053","article-title":"Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial","volume":"62","author":"Mottet","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0035","article-title":"A systematic review of oncological effectiveness and harms of primary local interventions for high-risk localized and locally advanced prostate cancer","author":"Van den Broeck","year":"2017","journal-title":"PROSPERO International Prospective Register of Systematic Reviews"},{"key":"10.1016\/j.eururo.2020.01.033_bib0040","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"89","author":"Moher","year":"2009","journal-title":"Phys Ther"},{"key":"10.1016\/j.eururo.2020.01.033_bib0045","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.eururo.2020.01.033_bib0050","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong Surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0055","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0060","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2012.02.049","article-title":"Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer","volume":"84","author":"Arcangeli","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0070","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.18.00154","article-title":"Time interval to biochemical failure as a surrogate end point in locally advanced prostate cancer: analysis of randomized trial NRG\/ RTOG 9202","volume":"37","author":"Dignam","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0080","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1464-410X.2010.09319.x","article-title":"Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years","volume":"105","author":"Iversen","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.01.033_bib0085","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG Oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0090","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0095","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijrobp.2017.02.027","article-title":"ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0105","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2010.04.065","article-title":"A randomized trial (Irish Clinical Oncology Research Group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer","volume":"81","author":"Armstrong","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0120","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0125","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijrobp.2015.05.024","volume":"93","author":"Rosenthal","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2020.01.033_bib0130","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1007\/s00432-006-0132-6","article-title":"The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer","volume":"132","author":"See","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0135","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijrobp.2015.09.020","article-title":"Outcome according to elective pelvic radiation therapy in patients with high-risk localized prostate cancer: A secondary analysis of the GETUG 12 phase 3 randomized trial","volume":"94","author":"Blanchard","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0145","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2020.01.033_bib0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2020.01.033_bib0155","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2020.01.033_bib0160","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0165","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2018.10.005","article-title":"Phase 2 randomized study of radiation therapy and 3-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients","volume":"103","author":"Carles","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0170","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0175","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.25900","article-title":"Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer","volume":"117","author":"Boorjian","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.01.033_bib0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/cam4.981","article-title":"Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer","volume":"6","author":"Miller","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.eururo.2020.01.033_bib0185","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1016\/j.ijrobp.2012.01.041","article-title":"Treatment outcomes in non-metastatic prostate cancer patients with ultra-high prostate-specific antigen","volume":"83","author":"Tai","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0190","first-page":"1","article-title":"Elderly patients aged \u226575 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis","author":"Sheng","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0195","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1442-2042.2012.03052.x","article-title":"Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population-based analysis","volume":"19","author":"Abdollah","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0200","first-page":"1","article-title":"Surgery vs radiotherapy in the management of biopsy Gleason score 9-10 prostate cancer and the risk of mortality","author":"Tilki","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0360-3016(99)00526-X","article-title":"Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation","volume":"47","author":"Stokes","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0210","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.eururo.2018.10.032","article-title":"Comparative effectiveness of radical prostatectomy versus external beam radiation therapy plus brachytherapy in patients with high-risk localized prostate cancer","volume":"75","author":"Berg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0215","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00345-018-2310-y","article-title":"Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer","volume":"36","author":"Bandini","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0220","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2010.10.003","article-title":"A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988\u20132006","volume":"59","author":"Abdollah","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0225","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2017.11.039","article-title":"Prostate cancer death after radiotherapy or radical prostatectomy: a nationwide population-based observational study","volume":"73","author":"Robinson","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0230","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bju.14780","article-title":"Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment","volume":"124","author":"Reichard","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.01.033_bib0235","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.ijrobp.2016.12.014","volume":"97","author":"Ciezki","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0240","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-530","article-title":"Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: Long-term follow-up","volume":"13","author":"Merino","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2020.01.033_bib0245","first-page":"9516","article-title":"Survival and secondary interventions following treatment for locally-advanced prostate cancer","volume":"25","author":"Sussman","year":"2018","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0250","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ijrobp.2006.06.019","article-title":"Case-Matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer","volume":"66","author":"Fletcher","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0255","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1245\/s10434-014-3780-9","article-title":"A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer","volume":"21","author":"Lee","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0119494","article-title":"Trends and outcome from radical therapy for primary non-metastatic prostate cancer in \u03b1 UK population","volume":"10","author":"Greenberg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2020.01.033_bib0265","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eururo.2018.02.012","article-title":"Effect of prostate cancer severity on functional outcomes after localized treatment: comparative effectiveness analysis of surgery and radiation study results","volume":"74","author":"Tyson","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0270","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.acuro.2018.07.007","article-title":"Oncological control in high-risk prostate cancer after radical prostatectomy and salvage radiotherapy compared to radiotherapy plus primary hormone therapy","volume":"43","author":"Ca\u00f1o-Velasco","year":"2019","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.eururo.2020.01.033_bib0275","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s10147-013-0654-2","article-title":"Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution","volume":"19","author":"Yamamoto","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0280","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1002\/cncr.31726","article-title":"Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer","volume":"124","author":"Jang","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.01.033_bib0285","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2017.08.011","article-title":"Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis","volume":"73","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0290","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urology.2013.08.081","article-title":"Treatment and 5-year survival in patients with nonmetastatic prostate cancer: the Norwegian experience","volume":"83","author":"Foss\u00e5","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2020.01.033_bib0295","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2147\/CMAR.S157442","article-title":"Survival outcomes of radical prostatectomy and external beam radiotherapy in clinically localized high-risk prostate cancer: a population-based, propensity score matched study","volume":"10","author":"Gu","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.eururo.2020.01.033_bib0300","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4143\/crt.2017.004","article-title":"Cancer-specific mortality among Korean men with localized or locally advanced prostate cancer treated with radical prostatectomy versus radiotherapy: a multi-center study using propensity scoring and competing risk regression analyses","volume":"50","author":"Koo","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.eururo.2020.01.033_bib0305","doi-asserted-by":"crossref","first-page":"g1502","DOI":"10.1136\/bmj.g1502","article-title":"Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes","volume":"348","author":"Sooriakumaran","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2020.01.033_bib0310","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.juro.2017.05.073","article-title":"Morbidity and mortality of locally advanced prostate cancer: a population based analysis comparing radical prostatectomy versus external beam radiation","volume":"198","author":"Feldman","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0315","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.acuro.2018.06.006","article-title":"Differences in overall survival and cancer-specific survival in high-risk prostate cancer patients according to the primary treatment","volume":"43","author":"Ca\u00f1o-Velasco","year":"2019","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.eururo.2020.01.033_bib0320","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/21681805.2019.1600580","article-title":"Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy","volume":"53","author":"Gunnarsson","year":"2019","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0325","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijrobp.2006.04.048","article-title":"Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer","volume":"66","author":"Zeliadt","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0330","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2010.04.004","article-title":"Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer","volume":"80","author":"Krauss","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0335","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0360-3016(00)01443-7","article-title":"Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy","volume":"49","author":"Horwitz","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0340","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijrobp.2012.11.024","article-title":"Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer","volume":"86","author":"Feng","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0345","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.22628","article-title":"Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate","volume":"109","author":"D\u2019Amico","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.01.033_bib0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.brachy.2009.04.007","article-title":"High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer","volume":"9","author":"Zwahlen","year":"2010","journal-title":"Brachytherapy"},{"key":"10.1016\/j.eururo.2020.01.033_bib0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers10090322","article-title":"High-dose-rate brachytherapy monotherapy versus image-guided intensity-modulated radiotherapy with helical tomotherapy for patients with localized prostate cancer","volume":"10","author":"Yamazaki","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2020.01.033_bib0360","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2018.10.013","article-title":"Ten-year survival after high-dose-rate brachytherapy combined with external beam radiation therapy in high-risk prostate cancer: a comparison with the Norwegian SPCG-7 cohort","volume":"132","author":"Wedde","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0365","first-page":"1","article-title":"Dose escalation of external beam radiotherapy for high-risk prostate cancer\u2014impact of multiple high-risk factor","author":"Umezawa","year":"2017","journal-title":"Asian J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0370","first-page":"2","article-title":"Comparison of image-guided intensity-modulated radiotherapy and low-dose rate brachytherapy with or without external beam radiotherapy in patients with localized prostate","volume":"8","author":"Tsubokura","year":"2018","journal-title":"Cancer Sci Rep"},{"key":"10.1016\/j.eururo.2020.01.033_bib0375","article-title":"Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer","volume":"91","author":"Tomita","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0380","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cncr.27784","article-title":"The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer","volume":"119","author":"Shilkrut","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.01.033_bib0385","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2011.09.055","article-title":"The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis","volume":"83","author":"Shen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2019.03.022","article-title":"Prostate-only versus whole-pelvis radiation with or without a brachytherapy boost for Gleason grade group 5 prostate cancer: a retrospective analysis","volume":"77","author":"Sandler","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2017.00185","article-title":"Propensity score matched comparison of intensity modulated radiation therapy vs stereotactic body radiation therapy for localized prostate cancer: a survival analysis from the National Cancer Database","volume":"7","author":"Ricco","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0400","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.ijrobp.2011.04.005","article-title":"Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer","volume":"82","author":"Pahlajani","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0405","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1002\/cncr.28213","article-title":"Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation","volume":"119","author":"Nguyen","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.01.033_bib0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12957-018-1395-5","article-title":"Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer","volume":"16","author":"Luo","year":"2018","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0415","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.brachy.2015.02.389","article-title":"Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: the impact of Gleason pattern 5","volume":"14","author":"Liss","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1016\/j.eururo.2020.01.033_bib0420","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bju.14223","article-title":"Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse","volume":"122","author":"Laing","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.01.033_bib0425","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ijrobp.2012.07.006","article-title":"Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer","volume":"85","author":"Khor","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0430","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.brachy.2019.01.013","article-title":"Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone","volume":"18","author":"Kent","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.eururo.2020.01.033_bib0435","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.brachy.2017.03.007","article-title":"Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer","volume":"16","author":"Jackson","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.eururo.2020.01.033_bib0440","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-015-0419-3","article-title":"The impact of increasing dose on overall survival in prostate cancer","volume":"10","author":"Hall","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0450","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00066-014-0806-y","article-title":"Comparing morbidity and cancer control after 3D-conformal (70\/74 Gy) and intensity modulated radiotherapy (78\/82 Gy) for prostate","volume":"191","author":"Dolezel","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0455","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ijrobp.2009.02.069","article-title":"Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?","volume":"76","author":"Bittner","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0460","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.juro.2015.11.005","article-title":"Survival outcomes of dose-escalated external beam radiotherapy versus combined brachytherapy for intermediate and high risk prostate cancer using the National Cancer Data Base","volume":"195","author":"Amini","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0465","first-page":"475","article-title":"The addition of chemotherapy in the definitive management of high risk prostate cancer","volume":"36","author":"Ferris","year":"2018","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.eururo.2020.01.033_bib0470","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s10147-017-1160-8","article-title":"Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution","volume":"22","author":"Fujita","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0475","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3892\/mco.2017.1204","article-title":"Determination of adequate pelvic lymph node dissection range for Japanese males undergoing radical prostatectomy","volume":"6","author":"Furubayashi","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0480","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/iju.12047","article-title":"Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer","volume":"20","author":"Linder","year":"2013","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0485","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s11255-018-1931-9","article-title":"Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population","volume":"50","author":"Sheng","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0490","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2017.08.015","article-title":"Erectile function and oncologic outcomes following open retropubic and robot-assisted radical prostatectomy: results from the LAParoscopic Prostatectomy Robot Open Trial","volume":"73","author":"Sooriakumaran","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0495","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2020.01.033_bib0500","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2008.20.3992","article-title":"Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease","volume":"27","author":"D\u2019Amico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0505","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamaoncol.2015.2316","article-title":"Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer","volume":"1","author":"Kalbasi","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0510","first-page":"235","article-title":"Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective","volume":"33","author":"Stewart","year":"2015","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.eururo.2020.01.033_bib0515","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ajur.2014.09.009","article-title":"Locally advanced and high risk prostate cancer: the best indication for initial radical prostatectomy?","volume":"1","author":"Van Poppel","year":"2014","journal-title":"Asian J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0520","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrurol.2014.100","article-title":"The status of surgery in the management of high-risk prostate cancer","volume":"11","author":"Bach","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0525","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.eururo.2012.02.031","article-title":"High-risk prostate cancer: from definition to contemporary management","volume":"61","author":"Bastian","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0530","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/21681805.2018.1520295","article-title":"SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer","volume":"52","author":"Stranne","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0535","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ijrobp.2018.08.001","article-title":"Comparative effectiveness of prostate cancer treatment options: limitations of retrospective analysis of Cancer Registry data","volume":"103","author":"Pearlstein","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.01.033_bib0540","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0545","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1200\/JCO.2019.37.15_suppl.5079","article-title":"CALGB 90203 (Alliance): radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC)","volume":"37","author":"Eastham","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0550","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"suppl_5","key":"10.1016\/j.eururo.2020.01.033_bib0555","first-page":"v325","article-title":"Docetaxel for hormone-na\u00efve prostate cancer (PCa): results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial","volume":"30","author":"James","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0560","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2018.07.027","article-title":"Systematic review of systemic therapies and therapeutic combinations with local treatments for high-risk localized prostate cancer","volume":"75","author":"Tosco","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0565","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0570","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1200\/JCO.2014.59.0026","article-title":"Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy","volume":"33","author":"Den","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2020.01.033_bib0575","first-page":"15","article-title":"The present and future of biomarkers in prostate cancer: proteomics, genomics, and immunology advancements","volume":"8","author":"Gaudreau","year":"2016","journal-title":"Biomark Cancer"},{"key":"10.1016\/j.eururo.2020.01.033_bib0580","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.juro.2013.06.017","article-title":"Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population","volume":"190","author":"Karnes","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2018.12.007","article-title":"Validation of the decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0590","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/pcan.2017.8","article-title":"Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project","volume":"20","author":"Tay","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2020.01.033_bib0595","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2018.01.001","article-title":"Focal therapy in primary localised prostate cancer: the European Association of Urology position in 2018","volume":"74","author":"van der Poel","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0600","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2017.08.016","article-title":"Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology","volume":"73","author":"Knoll","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.01.033_bib0605","first-page":"djv261","article-title":"The development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)","volume":"107","author":"Sweeney","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2020.01.033_bib0610","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.2014.17942","article-title":"Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer","volume":"313","author":"Siddiqui","year":"2015","journal-title":"JAMA"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820300713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820300713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:06:31Z","timestamp":1759583191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283820300713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":122,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0302283820300713"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2020.01.033","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}